Search Within

Sandra Pierina D'Angelo

  1. "Human Oncology and Pathogenesis Program"
Formats
  1. Meeting Abstract (35)
  2. Journal Article (32)
  3. Research Letter (2)
Groups
  1. Department of Medicine (69)
  2. GSK Faculty (69)
  3. Hematologic Malignancies, Division of (69)
  4. Human Oncology and Pathogenesis Program (69)
  5. Sarcoma Service (69)
  6. Solid Tumor Oncology Division (69)

More Groups

People
  1. Ping Chi (58)
  2. William Tap (57)
  3. Mark Dickson (55)
  4. Mrinal Gounder (54)
  5. Mary Keohan (53)
  6. Ciara Kelly (42)

More People

Years
  1. 2025 (1)
  2. 2024 (9)
  3. 2023 (8)
  4. 2022 (12)
  5. 2021 (2)
  6. 2020 (6)

More Years

Publications
  1. Journal of Clinical Oncology (30)
  2. Clinical Cancer Research (10)
  3. Annals of Oncology (5)
  4. JAMA Oncology (3)
  5. Journal of Thoracic Oncology (3)
  6. Nature Communications (3)

More Publications

Publishers
  1. American Society of Clinical Oncology (31)
  2. American Association for Cancer Research (11)
  3. Oxford University Press (7)
  4. Nature Publishing Group (6)
  5. American Medical Association (3)
  6. Elsevier Inc. (3)

More Publishers

Results (69)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Immune-related adverse events after immune checkpoint blockade-based therapy are associated with improved survival in advanced sarcomas
    Journal Article

    Rosenbaum, E.; Seier, K.; Bradic, M.; Kelly, C.; Movva, S.; Nacev, B. A.; Gounder, M. M.; Keohan, M. L.; Avutu, V.; Chi, P.; more...
    Cancer Research Communications (2023)

    Fulltext@MSK | Save
  • A phase II study of palbociclib combined with retifanlimab in patients with advanced dedifferentiated liposarcoma
    Meeting Abstract

    D'Angelo, S. P.; Rosenbaum, E.; Gularte MeĢrida, R.; Dickson, M. A.; Keohan, M. L.; Gounder, M. M.; Chi, P.; Movva, S.; Kelly, C. M.; Avutu, V.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • A phase II study of talimogene laherparepvec (T-VEC) and pembrolizumab in patients with advanced sarcoma: Results of expansion cohorts
    Meeting Abstract

    Kelly, C. M.; Avutu, V.; Chi, P.; Dickson, M. A.; Gounder, M. M.; Keohan, M. L.; Movva, S.; Rosenbaum, E.; Cordover, E.; Ariyan, C. E.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • A pilot study of lenvatinib plus pembrolizumab in patients with advanced sarcoma
    Meeting Abstract

    Movva, S.; Avutu, V.; Chi, P.; Dickson, M. A.; Gounder, M. M.; Kelly, Ciara M.; Keohan, M. L.; Meyers, P. A.; Cohen, S. M.; Hensley, M. L.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Interim results of a phase II trial of first line retifanlimab (R) plus gemcitabine and docetaxel (GD) in patients (pts) with advanced soft tissue sarcoma (STS)
    Meeting Abstract

    Rosenbaum, E.; Qin, L. X.; Dickson, M. A.; Keohan, M. L.; Gounder, M. M.; Chi, P.; Movva, S.; Kelly, C. M.; Avutu, V.; Chan, J. E.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Distinct genomic landscapes in radiation-associated angiosarcoma compared with other radiation-associated sarcoma histologies
    Journal Article

    Dermawan, J. K.; Chi, P.; Tap, W. D.; Rosenbaum, E.; D'Angelo, S.; Alektiar, K. M.; Antonescu, C. R.
    Journal of Pathology (2023)

    Fulltext@MSK | Save
  • Distinct genomic alterations in radiation-induced angiosarcoma compared to other radiation-associated sarcoma histologies: Rationale for individualized therapeutic targeting
    Meeting Abstract

    Dermawan, J.; Chi, P.; Tap, W.; Rosenbaum, E.; D'Angelo, S.; Alektiar, K.; Antonescu, C.
    Laboratory Investigation (2023)

    Fulltext@MSK | Save
  • A phase II study of epacadostat and pembrolizumab in patients with advanced sarcoma
    Journal Article

    Kelly, C. M.; Qin, L. X.; Whiting, K. A.; Richards, A. L.; Avutu, V.; Chan, J. E.; Chi, P.; Dickson, M. A.; Gounder, M. M.; Keohan, M. L.; more...
    Clinical Cancer Research (2023)

    Fulltext@MSK | Save
  • Targeted sequencing of 2,138 bone and soft tissue sarcomas reveals commonly altered pathways, subtype-independent genetic clusters, and potential therapeutic targets
    Meeting Abstract

    Nacev, B. A.; Sanchez-Vega, F.; Smith, S.; Antonescu, C.; Rosenbaum, E.; Shi, H.; Tang, C.; Socci, N.; Rana, S.; Gularte-Merida, R.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • A phase I/II trial of the PD-1 inhibitor retifanlimab (R) in combination with gemcitabine and docetaxel (GD) as first-line therapy in patients (Pts) with advanced soft-tissue sarcoma (STS)
    Meeting Abstract

    Rosenbaum, E.; Qin, L. X.; Thornton, K. A.; Movva, S.; Nacev, B. A.; Dickson, M. A.; Gounder, M. M.; Keohan, M. L.; Avutu, V.; Chi, P.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save